07 Jul Orthotopic GL261 glioma mouse model to test your immunomodulatory compound
In vivo glioma mouse model recapitulating key human glioblastoma characteristics provide an invaluable resource to assess novel immunotherapy-based strategies aiming at bolstering immune system functions to ultimately improve treatment outcome.
Our validated syngeneic glioma mouse model, based on the intracerebral inoculation of Luc2-expressing GL261 cells which allow tumor growth monitoring by bioluminescence imaging, represents a suitable tool for chemo- and immunotherapy assessment. It shows reproducible and predictable growth characteristics and closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration, tumor-induced immunosuppression and astrogliosis. Interestingly, the use of immunocompetent syngeneic host makes it well-suited for studying glioma immunology and testing innovative drug candidates for their efficacy in enhancing the anti-tumor response alone or combined with reference therapies.
Orthotopic GL261 glioma mouse model to test your immunomodulatory compound